Ludwig Cancer Research Presence at the Virtual AACR Annual Meeting April 9-14, 2021

sion Date	L MEETING - PANEL SESSIONS				
SIGN Date	Session Title	Presentation Title	Ludwig Location	Scientist	Session Time
9-Apr	Mechanistic aspects of immunotherapy efficacy versus resistance	N/A	Ludwig Chicago	Thomas Gajewski	12:05 AM - 11:59 PM EST
9-Apr	Alternative DNA Repair Pathways and Their Drug Targets	Targeting alternative pathways to overcome PARP inhibitor resistance	Ludwig Harvard	Alan D'Andrea	12:05 AM - 11:59 PM EST
10-Apr	Discovery Science Plenary: Mechanisms, Impact, and Exploitation of Cancer Chromosomal Instability	Mechanisms driving the rapid evolution of cancer genomes	Ludwig Harvard	David Pellman	9:38 AM - 10:00 AM EST
10-Apr	Integrative Data Analysis and Systems Modeling	Temporal and spatial topography of cell proliferation in cancer	Ludwig Harvard	Sandro Santagata and Peter Sorger	4:50 PM - 5:00 PM EST
11-Apr	Opening Plenary Session: Discovery Science Driving Clinical Breakthroughs	Paired presentation - Food for thought: A conversation about the role of diet in cancer	Ludwig MIT	Matthew Vander Heiden	10:47 AM - 11:09 AM EST
11-Apr	Clinical Trials with Novel Immuno-oncology Strategies	GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas	Ludwig Stanford	Michelle Monje	4:05 PM- 4:15 PM EST
11-Apr	Metabolic Pathways in Cancer	Fatty acid synthesis is required for breast cancer brain metastasis	Ludwig Harvard	Rakesh Jain	3:20 PM – 3:30PM EST
11-Apr	Developing and Applying Preclincal Cancer Models	Highly multiplexed, spatially resolved tissue imaging of genetically engineered mouse models of cancer to discover and characterize immune regulators of tumorigenesis	Ludwig Harvard	Sandro Santagata & Peter Sorger	2:35 PM - 2:45 PM EST
13-Apr	Patient-Derived Models for Cancer	Use of PDX models for preclinical cancer therapy studies	Ludwig Harvard	Joan Brugge	4:30 PM - 6:00 PM EST
13-Apr	Pathways to Early Detection of Pancreatic Cancer	N/A	Ludwig John Hopkins	Nickolas Papadopoulos	3:30 PM – 4:00 PM EST
14-Apr	Are There Cancer Stem Cells?	N/A	Ludwig Stanford	Irv Weissman	4:30 PM - 6:00 PM EST
14-Apr	Cancer Research	Meet the Editor	Ludwig Scientific Director	Chi Van Dang	2:00 PM -2:30 PM EST
15-Apr	Options and Opportunities for Treating Metastasis	Oligometastasis: Biologic basis and therapeutic opportunities	Ludwig Chicago	Ralph Weichselbaum	11:30 AM - 12:00 PM ES
15-Apr	Mobilizing antitumor immunity	Dharma Master Jiantai Symposium in Targeted Therapy: New Combinations of Targeted Therapies	Ludwig Lausanne	George Coukos	10:00 AM - 10:30 PM ES
	Cancer Immunometabolism	What Tregs eat makes them strong but vulnerable: Metabolic targeting of intramural Tregs for cancer treatment	Ludwig Lausanne	Ping-Chi Ho	11:30 AM to 12:00 PM E
CR 2021 ANNUA	L MEETING - POSTER SESSIONS				
10-Apr	Immune Cells in the Tumor Microenvironment	Hypoxia-induced lactate production by tumor-associated macrophages promote tumorigenesis	Ludwig Chicago	Lev Becker	8:30 AM -11:59 PM EST
10-Apr					
	Clinical Prevention, Early Detection, and Interception	Mutational landscape of the bronchial epithelium of individuals at high risk for lung cancer	Ludwig Stanford	Maximilian Diehn	8:30 AM - 11:59 PM EST
10-Apr	Clinical Prevention, Early Detection, and Interception Novel Assay Technology	Mutational landscape of the bronchial epithelium of individuals at high risk for lung cancer Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets	Ludwig Stanford Ludwig San Diego	Maximilian Diehn Frank Furnari	
·		Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug			8:30 AM - 11:59 PM EST
10-Apr	Novel Assay Technology	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial-	Ludwig San Diego	Frank Furnari	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST
10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung	Ludwig San Diego Ludwig MIT Ludwig Lausanne	Frank Furnari Frank Gertler	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST
10-Apr 10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1 Immune Mechanisms Invoked by Therapies	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model	Ludwig San Diego Ludwig MIT Ludwig Lausanne	Frank Furnari Frank Gertler Douglas Hanahan	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST
10-Apr 10-Apr 10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1 Immune Mechanisms Invoked by Therapies Tumor Suppressor Genes Modifiers of the Tumor Microenvironment	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model Lineage plasticity in small cell lung cancer generates non- neuroendocrine cells primed for vascular	Ludwig San Diego Ludwig MIT Ludwig Lausanne Ludwig MIT Ludwig MSK	Frank Furnari Frank Gertler Douglas Hanahan Tyler Jacks Taha Merghoub	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST
10-Apr 10-Apr 10-Apr 10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1 Immune Mechanisms Invoked by Therapies Tumor Suppressor Genes Modifiers of the Tumor Microenvironment Angiogenesis	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model Lineage plasticity in small cell lung cancer generates non- neuroendocrine cells primed for vascular mimicry	Ludwig San Diego Ludwig MIT Ludwig Lausanne Ludwig MIT Ludwig MSK Ludwig MIT	Frank Furnari Frank Gertler Douglas Hanahan Tyler Jacks Taha Merghoub Julien Sage	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM EST
10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1 Immune Mechanisms Invoked by Therapies Tumor Suppressor Genes Modifiers of the Tumor Microenvironment Angiogenesis Gene Expression	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model Lineage plasticity in small cell lung cancer generates non- neuroendocrine cells primed for vascular mimicry Oscillating p53 temporal dynamics enable proliferative recovery of cells following DNA damage	Ludwig San Diego Ludwig MIT Ludwig Lausanne Ludwig MIT Ludwig MSK Ludwig MIT Ludwig MIT	Frank Furnari Frank Gertler Douglas Hanahan Tyler Jacks Taha Merghoub Julien Sage Galit Lahav	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM
10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1 Immune Mechanisms Invoked by Therapies Tumor Suppressor Genes Modifiers of the Tumor Microenvironment Angiogenesis Gene Expression Immune Checkpoints Oncogenic Pathway-Mediated Regulation of Inflammation and	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model Lineage plasticity in small cell lung cancer generates non- neuroendocrine cells primed for vascular mimicry Oscillating p53 temporal dynamics enable proliferative recovery of cells following DNA damage Rapid highly multiplexed immunoprofiling of human fixed tissues by Orion imaging	Ludwig San Diego Ludwig MIT Ludwig Lausanne Ludwig MIT Ludwig MSK Ludwig MIT Ludwig Harvard Ludwig Harvard	Frank Furnari Frank Gertler Douglas Hanahan Tyler Jacks Taha Merghoub Julien Sage Galit Lahav Sandro Santagata & Peter Sorger	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM
10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1 Immune Mechanisms Invoked by Therapies Tumor Suppressor Genes Modifiers of the Tumor Microenvironment Angiogenesis Gene Expression Immune Checkpoints Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model Lineage plasticity in small cell lung cancer generates non- neuroendocrine cells primed for vascular mimicry Oscillating p53 temporal dynamics enable proliferative recovery of cells following DNA damage Rapid highly multiplexed immunoprofiling of human fixed tissues by Orion imaging Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma	Ludwig San Diego Ludwig MIT Ludwig Lausanne Ludwig MIT Ludwig MSK Ludwig MIT Ludwig Harvard Ludwig Harvard	Frank Furnari Frank Gertler Douglas Hanahan Tyler Jacks Taha Merghoub Julien Sage Galit Lahav Sandro Santagata & Peter Sorger Sandro Santagata & Peter Sorger	8:30 AM - 11:59 PM 8:30 AM - 11:59 PM 8:30 AM - 11:59 PM
10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr 10-Apr	Novel Assay Technology Invasion and Metastasis 1 Immune Mechanisms Invoked by Therapies Tumor Suppressor Genes Modifiers of the Tumor Microenvironment Angiogenesis Gene Expression Immune Checkpoints Oncogenic Pathway-Mediated Regulation of Inflammation and	Identification of efficacious treatment for glioblastoma (GBM) by applying computational drug sensitivity imputation to novel GBM avatars and GBM clinical datasets Implantable and insertable miniature dual-axis confocal (DAC) microscope to detect epithelial- mesenchymal transition (EMT) in the breast cancer microenvironment Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM model Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model Lineage plasticity in small cell lung cancer generates non- neuroendocrine cells primed for vascular mimicry Oscillating p53 temporal dynamics enable proliferative recovery of cells following DNA damage Rapid highly multiplexed immunoprofiling of human fixed tissues by Orion imaging	Ludwig San Diego Ludwig MIT Ludwig Lausanne Ludwig MIT Ludwig MSK Ludwig MIT Ludwig Harvard Ludwig Harvard	Frank Furnari Frank Gertler Douglas Hanahan Tyler Jacks Taha Merghoub Julien Sage Galit Lahav Sandro Santagata & Peter Sorger	8:30 AM - 11:59 PM EST 8:30 AM - 11:59 PM 8:30 AM - 11:59 PM